Shaoguang Li to Drug Resistance, Neoplasm
This is a "connection" page, showing publications Shaoguang Li has written about Drug Resistance, Neoplasm.
Connection Strength
0.470
-
Ma L, Pak ML, Ou J, Yu J, St Louis P, Shan Y, Hutchinson L, Li S, Brehm MA, Zhu LJ, Green MR. Prosurvival kinase PIM2 is a therapeutic target for eradication of chronic myeloid leukemia stem cells. Proc Natl Acad Sci U S A. 2019 05 21; 116(21):10482-10487.
Score: 0.145
-
Shan Y, DeSouza N, Qiu Q, Li S. Leukemia Stem Cells in Chronic Myeloid Leukemia. Adv Exp Med Biol. 2019; 1143:191-215.
Score: 0.142
-
Ma L, Shan Y, Bai R, Xue L, Eide CA, Ou J, Zhu LJ, Hutchinson L, Cerny J, Khoury HJ, Sheng Z, Druker BJ, Li S, Green MR. A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia. Sci Transl Med. 2014 Sep 03; 6(252):252ra121.
Score: 0.105
-
Peng C, Chen Y, Li D, Li S. Role of Pten in leukemia stem cells. Oncotarget. 2010 Jun; 1(2):156-160.
Score: 0.078